The China oncology drugs market was valued at $6,498.2 million in 2018 and is projected to reach $12,688.7 million by 2026, registering a CAGR of 8.7% from 2019 to 2026. Cancer is the second leading cause of death globally and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer according to the data published by WHO.
Being the most populous country in the world, cancer rates are significantly rising in China. As per Global Cancer Observatory in 2018, the number of new cancer cases registered each year in China are 4,285,033. Amongst which, lung cancer constitutes 18.1%; colorectum cancer is about 12.2%; stomach cancer is approximately 10.6%; liver cancer constitutes 9.2%; breast cancer comprises of 8.6% and 41.1% other cancers. The population of China accounts for 19.3% of the global population, and the incidence rate of cancer accounts for 22% of global cancer incidence, ranking first in the world. Cancer deaths in China account for about 27% of global cancer deaths. Cancer mortality in China is also higher than the global average of 17%.
Rise in incidence of various cancer conditions, aging population, westernized diet, shift to sedentary lifestyle, and surge in tobacco smoke exposure due to urbanization in China are the key factors that drive the growth of the cancer. This in turn boosts the growth of the China oncology drugs market.
Furthermore, rise in cancer awareness and increase in availability of cancer drugs are expected to boost the market growth. However, the use of traditional Chinese medicine (TCM) to cure cancer and high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies are expected to restrain the growth of the market. Conversely, high potential of emerging economies and increase in number of pipeline products are expected to provide new opportunities for market players in future.
The China oncology drugs market is segmented based on drug class type and indication. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy, and hormonal therapy. By indication, it is categorized into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer, ovarian cancer, cervical cancer, kidney cancer, and other cancers.
KEY MARKET BENEFITS
• This report entails a detailed quantitative analysis along with the current China oncology drugs market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market forecast is studied from 2019 to 2026.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
Key market segments
By Drug Class Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy Therapy
• Hormonal Therapy
By Indication
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Skin Cancer
• Ovarian Cancer
• Cervical Cancer
• Kidney Cancer
• Other Cancers
LIST of KEY PLAYERS PRofILED IN THE REPORT
• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Shanghai Junshi Biosciences Co., Ltd.
• Beigene
• Jiangsu Hengrui Medicine Co., Ltd
Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits For Stakeholders
1.3. Key Market Segments
1.3.1. List of Key Players Profiled In The Report
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies, 2018
3.3. Porter’S Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Industrial Collaboration
3.4.1.2. In House Manufacturing
3.4.1.3. Increase In Incidences of Cancers In The Chinese Population
3.4.2. Restraint
3.4.2.1. Preference of Generics And Biosimilars
3.4.3. Opportunity
3.4.3.1. Increase In Number of Pipeline Drugs
3.4.4. Impact Analyses
Chapter 4: China Oncology Drugs Market, By Drug Class Type
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Chemotherapy
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast
4.3. Targeted Therapy
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast
4.4. Immunotherapy (Biologic Therapy)
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast
4.5. Hormonal Therapy
4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast
Chapter 5: China Oncology Drugs Market, By Indication
5.1. Overview
5.1.1. Cancer Incidences In China, 2018
5.1.2. Market Size And Forecast
5.2. Blood Cancer
5.2.1. Market Size And Forecast
5.3. Breast Cancer
5.3.1. Market Size And Forecast
5.4. Gastrointestinal And Urinary Cancer
5.4.1. Market Size And Forecast
5.4.2. Gb/Cholangiocarcinoma
5.4.2.1. Market Size And Forecast
5.4.3. Bladder Cancer
5.4.3.1. Market Size And Forecast
5.4.4. Pancreatic Cancer
5.4.4.1. Market Size And Forecast
5.5. Prostate Cancer
5.5.1. Market Size And Forecast
5.6. Lung Cancer
5.6.1. Market Size And Forecast
5.6.2. Small Cell Lung Cancer (Sclc)
5.6.2.1. Market Size And Forecast
5.7. Skin Cancer
5.7.1. Market Size And Forecast
5.8. Ovarian Cancer
5.8.1. Market Size And Forecast
5.9. Cervical Cancer
5.9.1. Market Size And Forecast
5.10. Kidney Cancer
5.10.1. Market Size And Forecast,
5.11. Other Cancers
5.11.1. Market Size And Forecast
Chapter 6: Company Profiles
6.1. Abbvie Inc.
6.1.1. Company Overview
6.1.2. Company Snapshot
6.1.3. Operating Business Segments
6.1.4. Product Portfolio
6.1.5. Business Performance
6.2. Astellas Pharma Inc.
6.2.1. Company Overview
6.2.2. Company Snapshot
6.2.3. Operating Business Segments
6.2.4. Product Portfolio
6.2.5. Business Performance
6.3. Astrazeneca Plc
6.3.1. Company Overview
6.3.2. Company Snapshot
6.3.3. Operating Business Segments
6.3.4. Product Portfolio
6.3.5. Business Performance
6.4. Bristol-Myers Squibb Company
6.4.1. Company Overview
6.4.2. Company Snapshot
6.4.3. Operating Business Segments
6.4.4. Product Portfolio
6.4.5. Business Performance
6.4.6. Key Strategic Moves And Developments
6.5. Celgene Corporation
6.5.1. Company Overview
6.5.2. Company Snapshot
6.5.3. Operating Business Segments
6.5.4. Product Portfolio
6.5.5. Business Performance
6.5.6. Key Strategic Moves And Developments
6.6. F. Hoffmann-La Roche Ltd.
6.6.1. Company Overview
6.6.2. Company Snapshot
6.6.3. Operating Business Segments
6.6.4. Product Portfolio
6.6.5. Business Performance
6.6.6. Key Strategic Moves And Developments
6.7. Johnson & Johnson
6.7.1. Company Overview
6.7.2. Company Snapshot
6.7.3. Operating Business Segments
6.7.4. Product Portfolio
6.7.5. Business Performance
6.7.6. Key Strategic Moves And Developments
6.8. Shanghai Junshi Biosciences Co., Ltd.
6.8.1. Company Overview
6.8.2. Company Snapshot
6.8.3. Operating Business Segments
6.8.4. Product Portfolio
6.8.5. Business Performance
6.8.6. Key Strategic Moves And Developments
6.9. Beigene
6.9.1. Company Overview
6.9.2. Company Snapshot
6.9.3. Operating Business Segments
6.9.4. Product Portfolio
6.9.5. Business Performance
6.9.6. Key Strategic Moves And Developments
6.10. Jiangsu Hengrui Medicine Co., Ltd.
6.10.1. Company Overview
6.10.2. Company Snapshot
6.10.3. Operating Business Segments
6.10.4. Product Portfolio
6.10.5. Key Strategic Moves And Developments
